

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

Claims 1-37 (Canceled)

38. (New) A composition consisting of N-terminally truncated galectin-3, wherein the truncated galectin-3 begins with Leu-7 of SEQ ID NO:1 and extends to Ile-143 of SEQ ID NO:1 and a pharmaceutically acceptable carrier.
39. (New) The composition of claim 38, wherein the N-terminally truncated galectin-3 is effective to reduce tumor size.
40. (New) The composition of claim 38, wherein the N-terminally truncated galectin-3 is effective to reduce metastasis.
41. (New). The composition of claim 38, wherein the N-terminally truncated galectin-3 is effective to induce cell death in cancer cells.
42. (New) The composition of claim 38, wherein the N-terminally truncated galectin-3 is effective to inhibit inflammation.
43. (New) The composition of claim 38, wherein the N-terminally truncated galectin-3 is effective in inhibiting symptoms of rheumatoid arthritis.
44. (New) The composition of claim 38, wherein the composition is formulated for slow release.
45. (New) The composition of claim 38, wherein the N-terminally truncated galectin-3 is derivatized with one or more polyethylene glycol (PEG) molecules.

46. (New) The composition of claim 45, wherein the PEG molecules are attached to the N-terminally truncated galectin-3 on Cys-66 of SEQ ID NO:1.
47. (New) The composition of claim 45, wherein the PEG molecules are attached to the N-terminally truncated galectin-3 on a Cys residue added to the N-terminus.
48. (New) The composition according to claim 38, wherein the N-terminally truncated galectin-3 contains a conserved amino acid substitution at Val-95 of SEQ ID NO:1.
49. (New) The composition according to claim 38, wherein the composition consists of one or more additional agents.
50. (New) The composition according to claim 49, wherein the one or more additional agents are selected from the group consisting of an anti-inflammatory agent and an anti-cancer agent.